Podcasts about breast cancer symposium

- Updates from the 46th SABCS on Diagnostic Testing, Biomarkers, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 46th SABCS on Diagnostic Testing, Biomarkers, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 46th SABCS on Diagnostic Testing, Biomarkers, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 46th SABCS on Diagnostic Testing, Biomarkers, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

At the recent San Antonio Breast Cancer Symposium (SABCS), numerous updates were presented which have the potential to improve treatment outcomes for patients with breast cancer. After returning from the meeting, Dr. Jason Mouabbi, Assistant Professor of Breast Medical Oncology at MD Anderson Cancer Center and Editorial Board Member of Oncology Data Advisor, sat down to highlight some of the most exciting research presented, including the HER2CLIMB-02, MONARCH 3, and INAVO trials.

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Breast Cancer - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Genomics & Genetics of Breast Cancer - New Treatment Approaches for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Clinical Trial Updates - Key Questions to Ask Your Health Care Team - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Appointments, including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Breast Cancer - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Genomics & Genetics of Breast Cancer - New Treatment Approaches for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Clinical Trial Updates - Key Questions to Ask Your Health Care Team - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Appointments, including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Breast Cancer - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Genomics & Genetics of Breast Cancer - New Treatment Approaches for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Clinical Trial Updates - Key Questions to Ask Your Health Care Team - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Appointments, including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Breast Cancer - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Genomics & Genetics of Breast Cancer - New Treatment Approaches for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Symptoms, Discomfort & Pain - Clinical Trial Updates - Key Questions to Ask Your Health Care Team - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Appointments, including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Questions for Our Panel of Experts

San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, the research and vibrant discussions did not disappoint, with updates, controversies and complexities. Taking centre stage were PIK3CA mutation treatments, updates on CDK4/6 inhibitors and the age-old question - does exercise improve outcomes for our patients?Studies discussed in today's episode (subscription may be required)MONARCH-3KATHERINEINAVO120PREFERABLE EFFECTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world's leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry covers new research in breast cancer treatment, prevention, and survivorship presented at the 2022 San Antonio Breast Cancer Symposium, held December 6-10. Dr. Henry is a Professor and Interim Chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and is the Breast Oncology Disease Lead at the Rogel Cancer Center in Ann Arbor, Michigan. View Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of updates from the 2022 San Antonio Breast Cancer Symposium. I have no conflicts of interest for any of the trials that I will talk about today. First, I'm going to give a very brief overview of the types of breast cancer, and then talk about some research that was presented on both metastatic and early-stage breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We treat those cancers with anti-estrogen treatments, which block estrogen or lower estrogen levels. We often combine anti-estrogen treatments with other medications to try to make them work even better against the cancer. Other breast cancers are called HER2-positive. These are often more aggressive cancers, but because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2 receptors. These are called triple-negative breast cancer and are also often fairly aggressive cancers. One of the most exciting takeaways from the San Antonio meeting was the promise of new medications on the horizon to treat hormone receptor-positive, HER2-negative metastatic breast cancer. A commonly used treatment for metastatic breast cancer that is hormone receptor-positive and HER2-negative is fulvestrant, which is a type of medicine called “SERD,” or selective estrogen receptor degrader. At the meeting, we heard new data about 2 new SERD medications: elacestrant that was tested in the EMERALD trial and camizestrant that was tested in the SERENA trial, both of which are oral pills instead of injection medications and both of which may work particularly well against tumors that have mutations in the estrogen receptor called ESR1. In addition, we heard about capivasertib, which is an AKT inhibitor that was shown to work well when combined with fulvestrant and had less toxicity than some of the similar drugs that had previously been tested. For treatment of HER2-positive metastatic breast cancer, there are now a lot of medications that have been FDA approved, so some of the questions that clinical trials are now examining are related to what order we should use the medications in when we are treating patients. We heard about 2 studies of the medication trastuzumab deruxtecan, which I'm going to refer to as Enhertu. This drug is a combination of the anti-HER2 antibody trastuzumab plus a chemotherapy drug, and the antibody targets the drug to a cancer like a guided missile. Enhertu is currently routinely used to treat patients with metastatic HER2-positive breast cancer. We heard updated data that showed that when Enhertu was compared head-to-head against trastuzumab emtansine, also known as Kadcyla, patients who were treated with Enhertu were able to stay on the medication for a lot longer compared to patients who were treated with Kadcyla. We also heard that for patients who had already been treated with Kadcyla but it was no longer working, it is reasonable to switch to treatment with Enhertu at that point, because it is still likely to be effective. These studies may help oncologists decide what order to use these newer medications when treating patients with HER2-positive breast cancer. To switch gears a little bit, I'll now talk about another study I found interesting. This one is in the setting of people who are at high risk of developing breast cancer, but who haven't actually been diagnosed with cancer yet. In general, people are recommended to take either tamoxifen or an aromatase inhibitor medication, which is the same as treatment for patients who have been diagnosed with hormone receptor-positive breast cancer. But in this case, it's trying to prevent them from ever getting breast cancer in the first place. However, many people don't take the medications because they are concerned about side effects. A study was therefore performed in Italy that compared the 5-milligram dose of tamoxifen, which is only one-quarter of the full dose, with placebo for 3 years. After 7 years of follow-up, this low dose of tamoxifen, which is being referred to as “babytam,” was shown to reduce the risk of developing breast cancer by about half, which is similar to the effects seen with the full dose of the medication. Plus, there were fewer side effects. This lower dose is likely to be used regularly for prevention of breast cancer based on these findings, although this lower dose of tamoxifen has not yet been tested to see if it is as effective as the full dose of medication for preventing breast cancer recurrence, so it is not routinely recommended for patients who have a diagnosis of breast cancer to receive this lower dose. Finally, I will touch briefly on exciting results from the POSITIVE trial, which is a trial conducted around the world that examined whether it is safe for young women with hormone receptor-positive breast cancer to stop taking anti-hormone therapy to become pregnant. The women on this trial stopped taking endocrine therapy after taking it for about 18 to 30 months, and then spent up to 2 years trying to become pregnant. About three-quarters of the patients had at least 1 pregnancy during that time, and importantly, there was no increased risk of breast cancer recurrence seen in these patients. Once patients were done with their pregnancy, it was recommended that they restart taking endocrine therapy again. There were a lot of other research findings presented that were related to treatment for both early-stage and metastatic breast cancer at this meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, including the 3 that I mentioned already. And we eagerly await the results of large, randomized trials so that the drugs that work can be used to care for patients with breast cancer. But for now, that's it for this quick summary of important research from the 2022 San Antonio Breast Cancer Symposium. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

- Updates from the 45th SABCS on Diagnostic Testing, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 45th SABCS on Diagnostic Testing, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 45th SABCS on Diagnostic Testing, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

- Updates from the 45th SABCS on Diagnostic Testing, Precision Medicine, Grade & Hormone Receptors - What's New in the Treatment of ER, PR and HER2 Positive Breast Cancer - Updates from SABCS on: Hormone & Targeted Therapy - Chemotherapy Updates from SABCS - Investigational New Drugs in Clinical Trials - What's New in Prevention & Management of Treatment Side Effects, Discomfort, Neuropathy & Long Term Effects - Questions to Ask Your Health Care Team - Questions for Our Panel of Experts

Just in case you missed the San Antonio Breast Cancer Symposium adventures of Hayley Dinerman (Executive Director of The Triple Negative Breast Cancer Foundation), Ricki Fairley (Founder of TOUCH, The Black Breast Cancer Alliance) and host Melissa Berry, here's your chance to get the key takeaways and latest developments that we learned at this very important annual breast cancer conference. Thank you to our partners Gilead, Merck and Genentech for helping us to make this program possible!

Dr. Jason Mouabbi of the MD Anderson Cancer Center sits down with Oncology Data Advisor to go over updates and highlights from the recent San Antonio Breast Cancer Symposium (SABCS).

- Overview of Triple Negative Breast Cancer, in the Context of COVID-19 & Its Variants - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer, in the Context of COVID-19 & Its Variants - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer, in the Context of COVID-19 & Its Variants - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Triple Negative Breast Cancer, in the Context of COVID-19 & Its Variants - New Research on TNBC Presented at SABCS - Triple Negative Breast Cancer-Specific Treatment Updates - Updates on Clinical Trials in Advancing Treatment Choices - The Increasing Role of Diagnostic Testing, Biomarkers & Genetic Testing in Informing Treatment Options - Investigational New Therapies in Clinical Trials - New Developments in the Prevention & Management of Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with the Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, List of Questions, Adherence, Follow-Up Care & Discussion of OpenNotes - Questions for Our Panel of Experts

This year's San Antonio Breast Cancer Symposium took place last week. On this episode, we're hearing from the authors of three high-impact studies that were presented at the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

- Overview of Breast Cancer, in the Context of COVID-19 & Its Variants - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Breast Cancer Survivorship - Genomics & Genetics of Breast Cancer - New Treatment for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Discomfort & Pain - The Role of Clinical Trials - How Research Increases Treatment Options - Key Questions to Ask Your Healthcare Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Breast Cancer, in the Context of COVID-19 & Its Variants - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Breast Cancer Survivorship - Genomics & Genetics of Breast Cancer - New Treatment for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Discomfort & Pain - The Role of Clinical Trials - How Research Increases Treatment Options - Key Questions to Ask Your Healthcare Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Breast Cancer, in the Context of COVID-19 & Its Variants - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Breast Cancer Survivorship - Genomics & Genetics of Breast Cancer - New Treatment for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Discomfort & Pain - The Role of Clinical Trials - How Research Increases Treatment Options - Key Questions to Ask Your Healthcare Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Breast Cancer, in the Context of COVID-19 & Its Variants - New Research Presented at the San Antonio Breast Cancer Symposium (SABCS) - Breast Cancer Specific Treatment Updates - Early Stage Breast Cancer - Younger & Older People Living with Breast Cancer - Breast Cancer Survivorship - Genomics & Genetics of Breast Cancer - New Treatment for Metastatic Breast Cancer - Preventing & Managing Treatment Side Effects, Discomfort & Pain - The Role of Clinical Trials - How Research Increases Treatment Options - Key Questions to Ask Your Healthcare Team about Quality-of-Life Concerns - Questions for Our Panel of Experts

Melissa sits down with Hayley Dinerman, Executive Director of the Triple Negative Breast Cancer Foundation and Ricki Fairley, Founder of TOUCH, The National Breast Cancer Alliance to recap some of the most important takeaways from the San Antonio Breast Cancer Symposium. Learn how breast cancer advocacy groups, pharmaceutical companies and doctors are partnering to find a cure for Triple Negative Breast Cancer while keeping the patient community informed.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the world's leading professional organization for doctors who care for people with cancer. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests statements on this podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so the data described here may change as research progresses. In this podcast, Cancer.Net Associate Editor Dr. Norah Lynn Henry will discuss new research presented at the 2021 San Antonio Breast Cancer Symposium, held December 7-10. Dr. Henry is an Associate Professor in the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and is the Breast Oncology Disease Lead at the Rogel Cancer Center in Ann Arbor, Michigan. View Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. I'm here with exciting updates from the leading international breast cancer meeting, the San Antonio Breast Cancer Symposium, that was recently held in San Antonio, Texas, and online. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both metastatic and early- stage breast cancer. Then to wrap it up, I'm going to mention an interesting study looking at lymphedema. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive, and are stimulated to grow by the hormone estrogen. We treat those cancers with antiestrogen treatments, which block estrogen or lower estrogen levels. Other breast cancers are called HER2-positive. These are often more aggressive cancers, but because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2. These are called triple-negative breast cancers and are also often aggressive cancers. So first, I'm going to talk about treatment for HER2-positive metastatic breast cancer. Many of the treatment regimens that we use for treating patients with HER2-positive breast cancer include the antibody trastuzumab, which is also called herceptin. More recently, 2 drugs have been approved that include trastuzumab linked to a chemotherapy drug. So they're sort of like smart drugs. One is called trastuzumab emtansine and the other is called trastuzumab deruxtecan. In the DESTINY-Breast03 trial, which was presented earlier this year, the deruxtecan drug was shown to be more effective than the emtansine one. At this San Antonio meeting, the investigators look specifically at how well these 2 drugs worked in patients whose breast cancer had spread to their brain. And these exciting results, the deruxtecan drug was shown to greatly lengthen the time until cancer worsens compared to the emtansine drug, from 3 months on average to 15 months. In addition, on brain MRI, almost two-thirds of the patients had shrinkage of the brain lesions when they received the deruxtecan drug, compared to only about one-third who received emtansine. These important findings give us yet another potential treatment that we can use to help patients who have HER2-positive breast cancer that has spread to their brains. So next, I'm going to switch gears and talk about treatment of metastatic hormone receptor-positive breast cancer. At this time, the initial treatments are generally with antihormone drugs, such as aromatase inhibitors or fulvestrant. Unfortunately, these drugs often stop working, and then patients have to switch to chemotherapy medication. The good news is, that there are a number of new antihormone drugs currently being developed in the EMERALD trial, which was presented at this meeting. Investigators tested a new antihormone medicine called elacestrant in postmenopausal women with metastatic breast cancer whose cancer had previously worsened during treatment with medicines called CDK4/6 inhibitors plus antihormone treatment. These findings are exciting because this new drug may work against some cancers that no longer respond to a currently available antihormone medicines. It might mean they don't yet need to switch to chemotherapy. However, the findings are still early, and this drug is not yet approved by the FDA. I'm sure we'll hear more about this drug and other similar ones in the months and years to come. There were a lot of other research findings presented related to treatment for early- stage breast cancer at the meeting. And there were quite a number of updates from studies that were previously presented. For example, in patients with stage 2 and 3 triple-negative breast cancer, adding immunotherapy to neoadjuvant chemotherapy, which is chemotherapy given before surgery, improves event-free survival. Similarly, updated results from the RxPONDER clinical trial confirm that it is okay to not to give chemotherapy to postmenopausal women with hormone receptor-positive HER2-negative breast cancer who have 1 to 3 involved lymph nodes, and a 21-gene recurrence score of 25 or less. Finally, there was a report of a large clinical trial examining whether the diabetes drug, metformin, can decrease the risk of breast cancer recurrence, especially in hormone receptor-positive breast cancer. Unfortunately, taking metformin did not lower the risk of breast cancer recurrence compared to placebo. So it is not recommended that patients take this drug specifically to try to lower their risk of breast cancer coming back. In addition to these studies reporting findings about new medications, we also learn new information about an old problem, lymphedema. A group of women were followed over 2two years after they were diagnosed with breast cancer and underwent axillary lymph node dissection or removal of a large number of lymph nodes from under their armpit. Using a specific type of lymphedema measurement that looks at swelling in the arm, they found that almost 1 in 10 patients had developed lymphedema within 1 year of surgery, and almost 1 in 4 had lymphedema within 2 years. These are similar to what other studies had previously found. But importantly, patients who were Black were much more likely to develop lymphedema compared to white or Asian patients. This association with race hadn't been carefully looked at before and suggests that additional studies need to be done to figure out how best to monitor for, prevent, and treat lymphedema in all patients with breast cancer. Importantly, at this meeting, we also got glimpses of the many new drugs on the horizon for the treatment of breast cancer. And we eagerly await the results of large randomized trials so that the drugs at work can be used to care for patients with breast cancer. But for now, that's it for this quick summary of important research from the 2021 San Antonio Breast Cancer Symposium. Overall, we continue on a fast track in breast cancer with many new and exciting therapies being actively studied, as well as research helping support our patients to do better than ever. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. You can find more research from recent scientific meetings at www.cancer.net. And if this podcast was useful, please take a minute to subscribe, rate, and review the show wherever you listen to podcasts. This Cancer.Net podcast is part of the ASCO Podcast Network. This collection of 9 programs offers insight into the world of cancer care, covering a range of educational, inspirational, and scientific content. You can find all 9 shows, including this one, at podcast.asco.org. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping patients everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical School. The 2021 San Antonio Breast Cancer Symposium featured four days of presentations on the latest research on breast cancer. Dr. Tolaney joined us to discuss the research that is most immediately applicable to people who've been diagnosed with the disease. Listen to the episode to hear Dr. Tolaney explain: results of an early study looking at how effective the experimental medicine datopotamab deruxtecan was in treating metastatic, triple-negative breast cancer a study comparing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) to Kadcyla (chemical name: T-DM1 or ad-trastuzumab emtansine) for metastatic, HER2-positive breast cancer that had spread to the brain the studies that she thinks are practice-changing

The San Antonio Breast Cancer Symposium was held from December 7 to 10. On this episode, we'll hear from three authors of high-impact research that was presented during the meeting.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Proceedings from the second of 2 sessions on triple-negative breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy, moderated by Dr Neil Love.

Proceedings from the second of 2 sessions on HER2-positive breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy, moderated by Dr Neil Love.

The Oncology Journal Club - Delivering Oncology News DifferentlyThe Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 19 in our series The Oncology Journal Club.Today's podcast is a Special Episode focused on the recent San Antonio Breast Cancer Symposium 2020. Discussing the key papers are Eva Segelov, Craig Underhill, Amelia McCartney and Steve Vogl. With the usual top quality banter and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!Full bios and the list of all papers discussed are available on our website.For the latest oncology news visit www.oncologynews.com.au and for regular oncology updates for healthcare professionals, subscribe for free to get the weekly The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

The San Antonio Breast Cancer Symposium took place virtually from December 8 to 12th. This week, we're featuring three important studies from the meeting, focusing on a new prognostic tool; the treatment of depression and related symptoms in young breast cancer survivors; and a chemoimmunotherapy regimen for triple-negative disease.To listen to more podcasts from ASCO, visit asco.org/podcasts.

In this episode, we'll cover three important presentations from the San Antonio Breast Cancer Symposium. The first reports results from the HER2CLIMB trial on tucatinib, capecitabine, and trastuzumab for patients with HER2-positive metastatic breast cancer; the second discusses phase II findings on the activity of a novel HER2-targeting antibody-drug conjugate in HER2-positive metastatic breast cancer; and the third focuses on a postoperative treatment regimen for hormone receptor–positive, HER2-negative primary breast cancer.